<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459732</url>
  </required_header>
  <id_info>
    <org_study_id>2004-106</org_study_id>
    <secondary_id>K23HL076468</secondary_id>
    <nct_id>NCT00459732</nct_id>
    <nct_alias>NCT00480415</nct_alias>
  </id_info>
  <brief_title>Zinc &amp; Bone Health in Thalassemia: The Think Zinc Study</brief_title>
  <acronym>ThinkZn</acronym>
  <official_title>Zinc and Bone Metabolism in Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital &amp; Research Center Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether zinc can improve bone health in young patients
      with thalassemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is to determine if zinc supplementation improves bone health in
      young patients with thalassemia. Osteoporosis is a significant co-morbidity in patients with
      thalassemia which leads to decreased quality of life. The most effective way to prevent
      osteoporosis is to build strong, dense bones in the early years. A combination of disease,
      endocrine and nutritional factors likely contribute to the etiology of osteoporosis in this
      population. However, even well transfused patients with normal gonadal function who are
      supplemented with calcium have low bone mass. It is hypothesized that patients with
      thalassemia have low bone mass, in part, due to zinc deficiency. Sub-optimal zinc status has
      been identified in patients with thalassemia and zinc supplementation has been shown to
      improve linear growth. To test the primary hypothesis, an 18 month randomized
      placebo-controlled trial of zinc supplementation (25 mg Zn/day) vs. placebo will be conducted
      in 60 young patients (6-30 yrs) with thalassemia and low bone mass (spine BMD Z-score &lt;-1.0).
      Bone health, as estimated from measurements of bone mass (by DXA and pQCT) and markers of
      bone formation and resorption will be the primary outcome variables. This will be the first
      study to examine the effects of zinc supplementation on bone health in patients with
      thalassemia. If zinc supplementation is found to have a clinically important effect, this
      simple, safe, non-invasive therapy could quickly become a part of the standard care of these
      young patients and improve overall health in children and adult patients with thalassemia
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lumbar Spine Bone Mineral Density (BMD) by DXA (Baseline to 18 Months)</measure>
    <time_frame>0 to 18 months</time_frame>
    <description>Change in pa spine bone mineral density by DXA between baseline and 18 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Whole Body Bone Mineral Content (BMC) by DXA (Baseline to 18 Months)</measure>
    <time_frame>Baseline to 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin, a Marker of Bone Formation</measure>
    <time_frame>Baseline to 18 months</time_frame>
    <description>Absolute change in serum osteocalcin between 0 and 18 months, intention to treat analysis between the zinc and placebo groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>Placebo Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule, similar in size, shape and color to zinc capsule, taken once daily for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zinc (25 mg/d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg of elemental Zinc as zinc sulphate taken once daily for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>25 mg of elemental zinc as zinc sulphate take once daily for 18 months</description>
    <arm_group_label>Zinc (25 mg/d)</arm_group_label>
    <other_name>zinc sulphate</other_name>
    <other_name>elemental zinc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months</description>
    <arm_group_label>Placebo Capsule</arm_group_label>
    <other_name>&quot;sugar&quot; pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 to 30 years of age

          -  thalassemia

          -  bone mineral density Z-score &lt; -1.0 (by DXA)

        Exclusion Criteria:

          -  Bone marrow transplant recipient

          -  Currently prescribed treatment for low bone mass other than calcium or vitamin D (e.g.
             calcitonin, bisphosphonates)

          -  Currently prescribed zinc supplementation who are unable or unwilling to stop during
             this trial

          -  Currently participating in another trial with a medication known to affect bone
             mineral density.

          -  Chronic use of systemic corticosteroids

          -  Untreated hypogonadism or growth hormone deficiency

          -  Baseline serum copper &lt; 70 Âµg/dL

          -  Baseline vitamin D-25OH &lt; 11 ng/mL

          -  Pregnant or lactating at study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen B. Fung, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital &amp; Research Center Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center, Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2007</study_first_submitted>
  <study_first_submitted_qc>April 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2007</study_first_posted>
  <results_first_submitted>November 4, 2010</results_first_submitted>
  <results_first_submitted_qc>August 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2011</results_first_posted>
  <last_update_submitted>October 4, 2011</last_update_submitted>
  <last_update_submitted_qc>October 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>zinc, thalassemia, bone mineral density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 3 hematology clinics in the US between April, 2006 and May, 2008. 114 potentially eligible patients were screened, 43 were considered eligible and consented to participation.</recruitment_details>
      <pre_assignment_details>Following enrollment, prior to group assignment, subjects were screened for copper and vitamin D status. If serum copper was &lt;70ug/dL and/or 25OH vitamin D &lt;20ng/mL, they were placed on daily supplementation, 2 mg Cu/day and/or 1000 IU vitamin D/day.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Zinc</title>
          <description>25 mg of zinc as zn sulfate taken daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>daily capsule similar in size/color to zn was taken daily by this group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19">4 on zn dropped: 1 pregnant and 1 nausea after baseline, 1 lost to followup, 1 exited after 12 month</participants>
                <participants group_id="P2" count="14">3 on placebo dropped: 1 pregnant after 12 mo, 1 lost to followup, one died after 12 month timepoint</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zinc</title>
          <description>25 mg of zinc as zn sulfate taken daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>daily capsule similar in size/color to zn was taken daily by this group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.7" spread="5.6"/>
                    <measurement group_id="B2" value="17.4" spread="4.9"/>
                    <measurement group_id="B3" value="17.6" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Zinc</title>
          <description>Concentration of zinc within the plasma at baseline, mcg/dL</description>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" spread="11"/>
                    <measurement group_id="B2" value="79" spread="14"/>
                    <measurement group_id="B3" value="78" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spine Z-score</title>
          <description>Spine standard deviation score (Z-score) determined by baseline DXA bone density scan</description>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.9" spread="1.0"/>
                    <measurement group_id="B2" value="-2.4" spread="1.1"/>
                    <measurement group_id="B3" value="-2.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lumbar Spine Bone Mineral Density (BMD) by DXA (Baseline to 18 Months)</title>
        <description>Change in pa spine bone mineral density by DXA between baseline and 18 months</description>
        <time_frame>0 to 18 months</time_frame>
        <population>Intention to treat analysis of all subjects who completed the protocol in each arm of the study (zinc vs. placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Zinc</title>
            <description>25 mg of zinc as zn sulfate taken daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>daily capsule similar in size/color to zn was taken daily by this group</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lumbar Spine Bone Mineral Density (BMD) by DXA (Baseline to 18 Months)</title>
          <description>Change in pa spine bone mineral density by DXA between baseline and 18 months</description>
          <population>Intention to treat analysis of all subjects who completed the protocol in each arm of the study (zinc vs. placebo).</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="5.3"/>
                    <measurement group_id="O2" value="1.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Whole Body Bone Mineral Content (BMC) by DXA (Baseline to 18 Months)</title>
        <time_frame>Baseline to 18 months</time_frame>
        <population>Intention to treat analysis in those who completed the 18 month timepoint (zinc vs. placebo)</population>
        <group_list>
          <group group_id="O1">
            <title>Zinc</title>
            <description>25 mg of zinc as zn sulfate taken daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>daily capsule similar in size/color to zn was taken daily by this group</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Whole Body Bone Mineral Content (BMC) by DXA (Baseline to 18 Months)</title>
          <population>Intention to treat analysis in those who completed the 18 month timepoint (zinc vs. placebo)</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="6.1"/>
                    <measurement group_id="O2" value="2.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Osteocalcin, a Marker of Bone Formation</title>
        <description>Absolute change in serum osteocalcin between 0 and 18 months, intention to treat analysis between the zinc and placebo groups</description>
        <time_frame>Baseline to 18 months</time_frame>
        <population>Intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Zinc</title>
            <description>25 mg of zinc as zn sulfate taken daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>daily capsule similar in size/color to zn was taken daily by this group</description>
          </group>
        </group_list>
        <measure>
          <title>Osteocalcin, a Marker of Bone Formation</title>
          <description>Absolute change in serum osteocalcin between 0 and 18 months, intention to treat analysis between the zinc and placebo groups</description>
          <population>Intention to treat analysis</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="17.1"/>
                    <measurement group_id="O2" value="-4.3" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>ANCOVA</method>
            <method_desc>Repeated measures analysis of variance adjusted for baseline osteocalcin level.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Recorded between baseline and 18 month time point (end of study)</time_frame>
      <desc>Adverse events were collected at 5 timepoints, 3, 6, 12 and 18 months after start of supplementation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zinc</title>
          <description>25 mg of zinc as zn sulfate taken daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>daily capsule similar in size/color to zn was taken daily by this group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>One subject on the placebo arm of the trial died from cardiomyopathy secondary to iron overload after the 12 month time point.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue that is different that usual pre-transfusion fatigue</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Stomach Upset</sub_title>
                <description>Includes general stomach upset and/or cramping</description>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ellen Fung, PhD RD CCD</name_or_title>
      <organization>Children's Hospital &amp; Research Center, Oakland</organization>
      <phone>510-428-3885 ext 4939</phone>
      <email>efung@mail.cho.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

